A study published in journal Clinical Infectious Diseases shows that Avelox (moxifloxacin HCl) monotherapy is as powerful as a high dose combination regimen of ceftriaxon plus levofloxacin in the treatment of hospitalised patients with community-acquired pneumonia (CAP).
A total of 569 patients at 69 centres in 17 countries from Southern and Northern Europe, Latin America and South Africa were treated in the MOTIV trial (MOxifloxacin Treatment IV).
The prospective, multicentre, randomised, double-blind, noninferiority study, was sponsored by Bayer Schering Pharma and assessed by three independent committees of international experts.
“The results of MOTIV reinforce that moxifloxacin is an effective and well tolerated therapy for CAP patients in the hospital setting,” said Dr Antoni Torres, Professor of Pulmonology at the University of Barcelona (Spain) and one of the lead investigators of MOTIV.
“Moreover, the once-daily monotherapy provides a very convenient treatment option for the patient as well as for the healthcare professional.
“It was very important to see comparable clinical cure rates with moxifloxacin monotherapy when tested against a highly potent combined comparator regimen, and this study further
demonstrates the efficacy of moxifloxacin in treating CAP.”